Respondr TNF is the first test to predict an inflammatory bowel disease (IBD ... adalimumab and their biosimilars prior to therapy administration. Biologic medications that suppress the body's ...

Respondr(R) TNF Indicates Likelihood of Patient Response to Costly IBD Treatment Before Initiation ... adalimumab and their biosimilars prior to therapy administration. Biologic medications ...

The EC has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya to treat adults with ulcerative colitis (UC) ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

Biologics, including TNF inhibitors and vedolizumab, are indicated for treatment of IBD in the US ... or anti-TNF biologics as first-line therapy in UC and CD, from a Canadian public healthcare ...

Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results. See why I rate IMUX ...

Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn ...

Celltrion, Inc. today announced that six abstracts will be presented at the 2025 Digestive Disease Week® (DDW) Annual Meeting, taking place May 3-6 in San Diego, California. The oral and poster ...

Analysts have suggested that TL1A inhibitors could have blockbuster sales potential as second-line therapy for IBD refractory to first-line TNF biologics ... for other I&I indications.